600129.SH
太极集团
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 14.21
−5.71%Year over year
Reported trailing growth
- Revenue
- -7.3%
- EBITDA
- —
- EBIT
- +12.5%
- EPS
- +166.0%
- Free cash flow
- +90.1%
- Operating cash flow
- +155.1%
Forward estimates
Based on analyst estimates
- Revenue
- +42.8%
- EBITDA
- +275.4%
- EPS
- +964.2%
Three-year CAGR
- Revenue
- -9.4%
- EBITDA
- -6.5%
- EBIT
- -18.3%
- Net income
- -30.2%
- EPS
- -29.9%
- Free cash flow
- -63.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026